Low-fat dietary pattern and global cognitive function: Exploratory analyses of the Women's Health Initiative (WHI) randomized Dietary Modification trial

Rowan T Chlebowski, Steve Rapp, Aaron K Aragaki, Kathy Pan, Marian L Neuhouser, Linda G Snetselaar, JoAnn E Manson, Jean Wactawski-Wende, Karen C Johnson, Kathleen Hayden, Laura D Baker, Victor W Henderson, Lorena Garcia, Lihong Qi, Ross L Prentice, Rowan T Chlebowski, Steve Rapp, Aaron K Aragaki, Kathy Pan, Marian L Neuhouser, Linda G Snetselaar, JoAnn E Manson, Jean Wactawski-Wende, Karen C Johnson, Kathleen Hayden, Laura D Baker, Victor W Henderson, Lorena Garcia, Lihong Qi, Ross L Prentice

Abstract

Background: Meta-analyses of observational studies associate adherence to several dietary patterns with cognitive health. However, limited evidence from full scale, randomized controlled trials precludes causal inference regarding dietary effects on cognitive function.

Methods: The Women's Health Initiative (WHI) Dietary Modification (DM) randomized trial, in 48,835 postmenopausal women, included a subset of 1,606 WHI Memory Study (WHIMS) participants >= 65 years old, to assess low-fat dietary pattern influence on global cognitive function, evaluated with annual screening (Modified Mini-Mental State Examinations [3MSE]). Participants were randomized by a computerized, permuted block algorithm, stratified by age group and center, to a dietary intervention (40%) to reduce fat intake to 20% of energy and increase fruit, vegetable and grain intake or usual diet comparison groups (60%). The study outcome was possible cognition impairment (failed cognitive function screening) through the 8.5 year (median) dietary intervention. Those failing screening received a comprehensive, multi-phase cognitive function assessment to classify as: no cognitive impairment, mild cognitive impairment, or probable dementia. Exploratory analyses examined the composite endpoint of death after possible cognitive impairment through 18.7 years (median) follow-up. The WHI trials are registered at ClinicalTrials.gov:NCT00000611.

Findings: Among the 1,606 WHIMS participants, the dietary intervention statistically significantly reduced the incidence of possible cognitive impairment (n = 126; hazard ratio [HR] 0.59 95% confidence interval [CI] 0.38-0. 91, P = 0.01) with HR for dietary influence on subsequent mild cognitive impairment of 0.65 (95% CI 0.35-1.19) and HR of 0.63 (95% CI 0.19-2.10) for probable dementia (PD). Through 18.7 years, deaths from all-causes after possible cognitive impairment were non-significantly lower in the dietary intervention group (0.56% vs 0.77%, HR 0.83 95% CI 0.35 to 2.00, P = 0.16).

Interpretation: Adoption of a low-fat eating pattern, representing dietary moderation, significantly reduced risk of possible cognitive impairment in postmenopausal women.

Funding: Several Institutes of the US National Institutes of Health.

Keywords: Cognition; Dietary modification; Low-fat dietary pattern; Randomized clinical trial; Women's Health Initiative.

Conflict of interest statement

All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Chlebowski reported being a consultant for Novartis, AstraZeneca, Immunomedics, Amgen, Puma and Genentech.

© 2019 Published by Elsevier Ltd.

Figures

Fig. 1
Fig. 1
Participant flow diagram for the low-fat dietary intervention phase among the subset of DM trial participants that participated in WHIMS (n = 1606), an age eligible subset (age ≥ 65 years) of the WHI MHT trials. WHIMS = Women's Health Initiative Memory Study; MHT = menopausal hormone therapy; CEE = conjugated equine estrogen; MPA = medroxyprogesterone acetate.
Fig. 2
Fig. 2
Overall influence of the low-fat dietary intervention on possible cognitive impairment* during the intervention phase among the subset of DM trial participants that participated in WHIMS (n = 1606). The 7-year follow-up is over the dietary intervention phase of the trial (median, 7.2 [interquartile range {IQR}, 6.0–8.0] years). Summary statistics computed from Cox regression models stratified by 5-year age group, race/ethnicity, education, and randomization status in the WHI hormone therapy trials, using time from randomization as the time-scale. Subgroups were investigated, one at a time, by including an interaction term between randomization arm and subgroup with additional stratification of the baseline hazard by corresponding subgroup. P values corresponds to a two-sided score (log-rank) test of the dietary intervention's overall influence, or for the subgroup analysis, a test of interaction between the randomization group and corresponding subgroup. Percentages are annualized. * Possible cognitive impairment defined as transition to Phase 2 of the WHIMS protocol. After completion of Phases 2 and 3, typically within 3 months possible cognitive impairment, participants were classified as probable dementia, mild cognitive impairment, or no cognitive impairment. † Ever used menopausal hormone therapy or randomized to CEE or CEE+MPA arm of WHI hormone trial.  ^ Among women randomized to either WHI hormone therapy trial. WHIMS = Women's Health Initiative Memory Study; HR = hazard ratio; CI = confidence interval.
Fig. 3
Fig. 3
Kaplan-Meier estimates of the cumulative hazard for possible cognitive impairment* during the intervention phase among the subset of DM trial participants that participated in WHIMS (n = 1606). The 7-year follow-up is over the dietary intervention phase of the trial (median, 7.2 [interquartile range {IQR}, 6.0–8.0] years). Summary statistics computed from a Cox regression model stratified by 5-year age group, race/ethnicity, education, and randomization status in the WHI hormone therapy trials, using time from randomization as the time-scale. P-value corresponds to a two-sided score (log-rank) test of the dietary intervention's overall influence. Percentages are annualized. * Possible cognitive impairment defined as transition to Phase 2 of the WHIMS protocol. After completion of Phases 2 and 3, typically within 3 months of possible cognitive impairment, participants were classified as probable dementia, mild cognitive impairment, or no cognitive impairment. WHIMS = Women's Health Initiative Memory Study; HR = hazard ratio; CI = confidence interval.

References

    1. Prince M., Ali G.C., Guerchet M., Prina A.M., Albanese E., Wu Y.T. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther. 2016;8(1):23.
    1. World Health Organization and Alzheimer's Disease International. Dementia: A Public Health Priority. Geneva: World Health Organization; 2012. pp. 92-93.
    1. Frankish H., Horton R. Prevention and management of dementia: a priority for public health. Lancet. 2017;390(10113):2614–2615.
    1. Williams J.W., Plassman B.L., Burke J., Benjamin S. Preventing alzheimer's disease and cognitive decline. Evid Rep Technol Assess (Full Rep) 2010;193:1–727.
    1. Lindenberger U. Human cognitive aging: corriger la fortune? Science. 2014;346(6209):572–578.
    1. Klimova B., Valis M. Nutritional interventions as beneficial strategies to delay cognitive decline in healthy older individuals. Nutrients. 2018;10(7)
    1. Wahl D., Coogan S.C., Solon-Biet S.M., de Cabo R., Haran J.B., Raubenheimer D. Cognitive and behavioral evaluation of nutritional interventions in rodent models of brain aging and dementia. Clin Interv Aging. 2017;12:1419–1428.
    1. Ledreux A., Wang X., Schultzberg M., Granholm A.C., Freeman L.R. Detrimental effects of a high fat/high cholesterol diet on memory and hippocampal markers in aged rats. Behav Brain Res. 2016;312:294–304.
    1. Okereke O.I., Rosner B.A., Kim D.H., Kang J.H., Cook N.R., Manson J.E. Dietary fat types and 4-year cognitive change in community-dwelling older women. Ann Neurol. 2012;72(1):124–134.
    1. Barnard N.D., Bunner A.E., Agarwal U. Saturated and trans fats and dementia: a systematic review. Neurobiol Aging. 2014;35 Suppl(2):S65–S73.
    1. Beilharz J.E., Maniam J., Morris M.J. Diet-Induced cognitive deficits: the role of fat and sugar, potential mechanisms and nutritional interventions. Nutrients. 2015;7(8):6719–6738.
    1. Ding B., Xiao R., Ma W., Zhao L., Bi Y., Zhang Y. The association between macronutrient intake and cognition in individuals aged under 65 in china: a cross-sectional study. BMJ Open. 2018;8(1)
    1. Shumaker S.A., Reboussin B.A., Espeland M.A., Rapp S.R., McBee W.L., Dailey M. The women's health initiative memory study (WHIMS): a trial of the effect of estrogen therapy in preventing and slowing the progression of dementia. Control Clin Trials. 1998;19(6):604–621.
    1. Anderson G.L., Manson J., Wallace R., Lund B., Hall D., Davis S. Implementation of the women's health initiative study design. Ann Epidemiol. 2003;13(9 Suppl):S5–17.
    1. Prentice R.L., Caan B., Chlebowski R.T., Patterson R., Kuller L.H., Ockene J.K. Low-fat dietary pattern and risk of invasive breast cancer: the women's health initiative randomized controlled dietary modification trial. JAMA. 2006;295(6):629–642.
    1. Shumaker S.A., Legault C., Rapp S.R., Thal L., Wallace R.B., Ockene J.K. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the women's health initiative memory study: a randomized controlled trial. JAMA. 2003;289(20):2651–2662.
    1. Teng E.L.C.H., Gong A. Comparisons between the mini-mental state exam (MMSE) and its modified version: the 3MS test. In: Hasegawa K.H.A., editor. Psychogeriatrics biomedical and social advances. Excerpta Medica; Tokyo, Japan: 1990. pp. 189–192.
    1. Bland R.C., Newman S.C. Mild dementia or cognitive impairment: the modified mini-mental state examination (3MS) as a screen for dementia. Canadian Journal of Psychiatry Revue Canadienne de Psychiatrie. 2001;46(6):506–510.
    1. Shumaker S.A., Legault C., Kuller L., Rapp S.R., Thal L., Lane D.S. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: women's health initiative memory study. JAMA. 2004;291(24):2947–2958.
    1. Livingston G., Sommerlad A., Orgeta V., Costafreda S.G., Huntley J., Ames D. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–2734.
    1. Morris J.C., Heyman A., Mohs R.C., Hughes J.P., van Belle G., Fillenbaum G. The consortium to establish a registry for alzheimer's disease (CERAD). part I. clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39(9):1159–1165.
    1. Espeland M.A., Rapp S.R., Shumaker S.A., Brunner R., Manson J.E., Sherwin B.B. Conjugated equine estrogens and global cognitive function in postmenopausal women: women's health initiative memory study. JAMA. 2004;291(24):2959–2968.
    1. Bowen J., Teri L., Kukull W., McCormick W., McCurry S.M., Larson E.B. Progression to dementia in patients with isolated memory loss. Lancet. 1997;349(9054):763–765.
    1. Gaussoin S.A., Espeland M.A., Absher J., Howard B.V., Jones B.M., Rapp S.R. Ascertaining dementia-related outcomes for deceased or proxy-dependent participants: an overview of the women's health initiative memory study supplemental case ascertainment protocol. Int J Geriatr Psychiatry. 2012;27(2):205–214.
    1. Prentice R.L., Kalbfleisch J.D., Peterson A.V., Jr., Flournoy N., Farewell V.T., Breslow N.E. The analysis of failure times in the presence of competing risks. Biometrics. 1978;34(4):541–554.
    1. Chlebowski R.T., Anderson G.L., Gass M., Lane D.S., Aragaki A.K., Kuller L.H. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684–1692.
    1. Anderson G.L., Chlebowski R.T., Aragaki A.K., Kuller L.H., Manson J.E., Gass M. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the women's health initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13(5):476–486.
    1. Chlebowski R.T., Aragaki A.K., Anderson G.L., Thomson C.A., Manson J.E., Simon M.S. Low-Fat dietary pattern and breast cancer mortality in the women's health initiative randomized controlled trial. J Clin Oncol: Off J Am Soc Clin Oncol. 2017;35(25):2919–2926.
    1. Cespedes Feliciano E.M., Prentice R.L., Aragaki A.K., Neuhouser M.L., Banack H.R., Kroenke C.H. Methodological considerations for disentangling a risk factor's influence on disease incidence versus postdiagnosis survival: the example of obesity and breast and colorectal cancer mortality in the women's health initiative. Int J Cancer. 2017;141(11):2281–2290.
    1. Wang R., Lagakos S.W., Ware J.H., Hunter D.J., Drazen J.M. Statistics in medicine — reporting of subgroup analyses in clinical trials. New Engl J Med. 2007;357(21):2189–2194.
    1. Feart C., Samieri C., Rondeau V., Amieva H., Portet F., Dartigues J.F. Adherence to a mediterranean diet, cognitive decline, and risk of dementia. JAMA. 2009;302(6):638–648.
    1. van den Brink A.C., Brouwer-Brolsma E.M., Berendsen A.A.M., van de Rest O. The mediterranean, dietary approaches to stop hypertension (DASH), and mediterranean-dash intervention for neurodegenerative delay (MIND) diets are associated with less cognitive decline and a lower risk of alzheimer's disease-a review. Adv Nutr (Bethesda, MD) 2019
    1. Chen X., Maguire B., Brodaty H., O'Leary F. Dietary patterns and cognitive health in older adults: a systematic review. J Alzheimer's Dis: JAD. 2019;67(2):583–619.
    1. Daviglus M.L., Bell C.C., Berrettini W., Bowen P.E., Connolly E.S., Jr., Cox N.J. National institutes of health state-of-the-science conference statement: preventing alzheimer disease and cognitive decline. Ann Intern Med. 2010;153(3):176–181.
    1. Martinez-Lapiscina E.H., Clavero P., Toledo E., Estruch R., Salas-Salvado J., San Julian B. Mediterranean diet improves cognition: the predimed-navarra randomised trial. J. Neurol. Neurosurg. Psychiatr. 2013;84(12):1318–1325.
    1. Ngandu T., Lehtisalo J., Solomon A., Levalahti E., Ahtiluoto S., Antikainen R. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015;385(9984):2255–2263.
    1. Andrieu S., Guyonnet S., Coley N., Cantet C., Bonnefoy M., Bordes S. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;16(5):377–389.
    1. Marseglia A., Xu W., Fratiglioni L., Fabbri C., Berendsen A.A.M., Bialecka-Debek A. Effect of the nu-age diet on cognitive functioning in older adults: a randomized controlled trial. Front Physiol. 2018;9:349.
    1. Sacks F.M., Svetkey L.P., Vollmer W.M., Appel L.J., Bray G.A., Harsha D. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium collaborative research group. N Engl J Med. 2001;344(1):3–10.
    1. WHO Guidelines Approved by the Guidelines Review Committee . Vol. 2019. World Health Organization (c) World Health Organization; Geneva: 2019. (Risk reduction of cognitive decline and dementia: who guidelines).
    1. Howard B.V., Aragaki A.K., Tinker L.F., Allison M., Hingle M.D., Johnson K.C. A low-fat dietary pattern and diabetes: a secondary analysis from the women's health initiative dietary modification trial. Diabet Care. 2018;41(4):680–687.
    1. Nasreddine Z.S., Phillips N.A., Bedirian V., Charbonneau S., Whitehead V., Collin I. The montreal cognitive assessment, moca: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699.
    1. Garcia-Ptacek S., Kareholt I., Cermakova P., Rizzuto D., Religa D., Eriksdotter M. Causes of death according to death certificates in individuals with dementia: a cohort from the swedish dementia registry. J Am Geriatr Soc. 2016;64(11):e137–ee42.
    1. Espeland M.A., Bryan R.N., Goveas J.S., Robinson J.G., Siddiqui M.S., Liu S. Influence of type 2 diabetes on brain volumes and changes in brain volumes: results from the women's health initiative magnetic resonance imaging studies. Diabetes Care. 2013;36(1):90–97.
    1. Ng T.P., Feng L., Nyunt M.S., Feng L., Gao Q., Lim M.L. Metabolic syndrome and the risk of mild cognitive impairment and progression to dementia: follow-up of the singapore longitudinal ageing study cohort. JAMA Neurol. 2016;73(4):456–463.
    1. Allison M.A., Aragaki A.K., Ray R.M., Margolis K.L., Beresford S.A., Kuller L. A randomized trial of a low-fat diet intervention on blood pressure and hypertension: tertiary analysis of the whi dietary modification trial. Am J Hypertens. 2016;29(8):959–968.
    1. Neuhouser M.L., Howard B., Lu J., Tinker L.F., Van Horn L., Caan B. A low-fat dietary pattern and risk of metabolic syndrome in postmenopausal women: the women's health initiative. Metab Clin Exp. 2012;61(11):1572–1581.
    1. Howard B.V., Manson J.E., Stefanick M.L., Beresford S.A., Frank G., Jones B. Low-fat dietary pattern and weight change over 7 years: the women's health initiative dietary modification trial. JAMA. 2006;295(1):39–49.

Source: PubMed

3
Suscribir